Extracellular Vesicles Drive Endothelial and Tubular Injury in Cardiac Surgery-Associated Acute Kidney Injury

Cardiac surgery utilizing cardiopulmonary bypass (CPB) is a cornerstone procedure, yet it frequently leads to cardiac surgery-associated acute kidney injury (CSA-AKI), affecting up to 30% of patients and necessitating renal replacement therapy in 2-5% of cases. CSA-AKI is a major predictor of morbidity, extending ICU stays, increasing healthcare costs, elevating short-term mortality nearly five-fold, and predisposing survivors to chronic kidney disease (CKD). The lack of effective pharmacological treatments highlights a critical gap in understanding its underlying molecular pathophysiology, which has historically been attributed primarily to hemodynamic perturbations during CPB.

The provided abstract focuses on the introduction and background of cardiac surgery-associated acute kidney injury (CSA-AKI) and the emerging role of extracellular vesicles (EVs) as mediators of injury. It does not detail specific experimental methods, study design, animal models, doses, or primary endpoints for a novel study. Therefore, no specific protocol or experimental setup can be reported from this text.

The provided abstract serves as an introduction to the topic of extracellular vesicles (EVs) as mediators of endothelial and tubular injury in cardiac surgery-associated acute kidney injury (CSA-AKI). It does not present novel experimental findings, specific quantitative results, p-values, or statistical data from a new study. The text primarily outlines the clinical significance of CSA-AKI and the historical understanding of its pathophysiology, setting the stage for a discussion on EVs as a new mechanistic paradigm.